Kesimpta can interact with teriflunomide (Aubagio). Both drugs are used to treat MS and CIS. Kesimpta and teriflunomides can both increase your risk of infection when you use them individually.

Teriflunomide (Aubagio) was approved by the FDA in 2012 for MS. Like fingolimod, it is administered as a daily pill. Teriflunomide has modest efficacy on preventing relapses but may help more with ...

The European Commission has given the go-ahead to Aubagio (teriflunomide) for patients with relapsing/remitting forms of MS aged 10 to 17, in addition to its existing indication for adults aged 18 ...

Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor ...

While Sanofi's list price of Aubagio is set at £13,529 ($22,100) per patient a year, NICE was able to recommend it for the NHS after Sanofi made the drug available at a discount under the patient ...